|
U.S. Compounding Pharmacies Market |
In general, a compounding pharmacist mixes, alters, or otherwise creates medication according to a doctor’s prescription. They can add or remove ingredients that aren’t suitable for a patient or change the form of a drug, such as turning a pill into a liquid.
Some compounding pharmacies produce non-sterile preparations like creams, ointments, and lozenges, while others specialize in making sterile products such as injections and eye drops. Some compounding pharmacies can recreate or formulate drugs that have been discontinued by larger manufacturers.
According to Coherent Market Insights, U.S. Compounding Pharmacies Market is estimated to be valued at US$ 4,789.6 million in 2022 and is expected to exhibit a CAGR of 5.9 % during the forecast period (2022-2030).
This can be helpful in situations when a drug shortage arises, as it allows people who are currently receiving that medication to continue with treatment without interruption. It is more cost-effective to produce compounded drugs for individual patients than to mass-produce them for general distribution.
Market Dynamics:
The rising adoption of inorganic growth strategies by key players is estimated to augment the growth of the global U.S. compounding pharmacies market during the forecast period. For instance, B Braun and Grifols entered into a strategic alliance in November 2020. Under this alliance, they will be integrating Grifols’ automated compounding portfolio and B Braun’s Safe Infusion Systems, in order to ensure the safety of automated drug delivery. Moreover, the rising cost of maintenance and lack of efficient regulations is anticipated to restrain the growth of the global U.S. Compounding Pharmacies Market during the forecast period.
Impact of COVID-19:
The pandemic was first reported in China and later on, it spread to other parts of the world. It affected the global economy in an adverse manner. The pandemic also impacted the growth of several businesses. Manufacturing activities in many sectors were hated due to the strict restrictions imposed. These restrictions also hampered the healthcare sector, as the number of COVID-19 cases was increasing on a daily basis. There was a shortage of drugs, medical equipment, and skilled professionals in many nations during the pandemic. There was a rise in demand for compounding pharmacies, for treating COVID-19 patients. Thus, the pandemic had a positive impact on the growth of the global .S. compounding pharmacies market.
Key Takeaways:
The global U.S. Compounding Pharmacies Market is estimated to witness high growth, exhibiting a CAGR of 5.9 % over the forecast period, due to increasing acquisition by key players. For instance, Fresenius Kabi acquired mAbxience in March 2022. This will enhance Kabi's presence in the biopharmaceuticals market.
North America is anticipated to witness significant growth in the global U.S. Compounding Pharmacies Market during the forecast period, due to growing adoption among people and the increasing presence of several compounding pharmacies.
The increasing number of eye diseases and eye disorders is expected to boost the growth of the global Eye Health Supplements Market over the forecast period.
Key players active in the global U.S. compounding pharmacies market are Valor Compounding Pharmacy, Braun, ITC Compounding Pharmacy, Athenex Pharma Solutions, Pencol Compounding Pharmacy, Fresenius Kabi, Mcguff compounding pharmacy services, Clinigen Group PLC, Institutional Pharmacy Solutions, Dougherty's Pharmacy, Inc., Rx3 Compounding Pharmacy, Lorraine's Pharmacy, and Nephron Pharmaceuticals Corporation.
Comments
Post a Comment